## CAN ULTRASOUND ENHANCE THE RECANALIZATION EFFECT OF tPA?: YES Elsa Azevedo

Department of Neurology, São João Hospital Centre and Faculty of Medicine of University of Porto, Portugal

Stroke is the first cause of disability worldwide. Intravenous thrombolysis with alteplase has changed the acute stroke treatment paradigm in the 21th century. It is still the first treatment with proven efficacy that we should give in most instances, whenever possible, in the first 4.5h after symptoms onset <sup>1</sup>.

However, even in these treated patients the results are not satisfactory. In an international registry (SITS) including patients treated with alteplase in daily routine, 46% of patients still have disability at 3 months, being dependent on others, or are even dead<sup>2</sup>.

The main reason for this lack of efficacy is the modest recanalization rate of the occluded artery with intravenous thrombolysis, being about 25-40%<sup>3</sup>. On the other hand, it is well-known that the speed of recanalization is crucial for the success of clinical recovering<sup>4</sup>.

Searching for alternative treatments, thrombolytic drugs have been administered locally, although there is not a good evidence of a greater efficacy of intra-arterial tPA<sup>5</sup>. More recently, mechanical thrombectomy has been shown to be safe and significantly improve ischemic stroke patients' outcome, when treated in the first 6 hours from symptoms onset<sup>6</sup>. Nevertheless, this endovascular treatment requires a highly specialized organization and very well-trained neuro-interventionists, only available in some centers.

On the other hand, most stroke units have access to transcranial Doppler (TCD) devices, and vascular neurologists are often familiarized with this simple, harmless, bedside technique. TCD assists in localizing the occlusion site, evaluating the cerebral hemodynamics, identifying patients with high risk for no recanalization with iv-tPA, monitoring the effect of this drug, and can even assist in enhancing the recanalization effect of tPA.

Sonothrombolysis, the use of ultrasound to help dissolve the clot at arterial occlusion, is an innovative reperfusion therapy in acute ischemic stroke. The finding that monitoring patients with TCD during the administration of intravenous tPA increased the rate of recanalization<sup>7</sup> launched multiple clinical trials.

Augmentation of recanalization can be achieved safely combining tPA with diagnostic transcranial Doppler, which delivers mechanical pressure waves to the thrombus, exposing more its surface and thus increasing the penetration of circulating tPA into the thrombus.

In the CLOTBUST trial<sup>8</sup>, 83% of patients achieved any recanalization (46% complete, 27% partial) with tPA+TCD vs 50% (17% complete, 33% partial) with tPA alone within 2 hours of treatment (P=0.001). Sustained, complete recanalization at 2 hours was 38% vs 13%, respectively (P=0.03).

The treatment of acute ischemic stroke can be further improved by ultrasound and microbubbles in combination with thrombolytic drugs. Molina<sup>9</sup> has shown that administration of microbubbles induces further acceleration of US-enhanced thrombolysis in acute stroke, leading to a more complete recanalization and to a trend toward better short- and long-term outcome. Most excitingly, ultrasound and microbubbles may be effective in clot lysis of ischemic stroke even without additional thrombolytic drugs<sup>10</sup>.

A meta-analysis<sup>11</sup> of 6 randomized and 3 nonrandomized clinical studies of sonothrombolysis showed that any diagnostic ultrasound monitoring can at least double the chance of early complete arterial recanalization at no increase in the risk of symptomatic intracerebral hemorrhage.

Also a recent Cochrane review<sup>12</sup> of all the randomized studies published on ST reported significantly more recanalization and better clinical outcome, with no effect on mortality, when ST was added to alteplase in acute ischemic stroke treatment.

An interesting recent study<sup>13</sup> compared the efficacy of different acute reperfusion therapies for acute ischemic stroke, in a comprehensive benefit-risk analysis of 13 randomized and 5 nonrandomized clinical trials. It concluded that intravenous thrombolysis with tenecteplase and sonothrombolysis had the higher benefit-to-risk ratio among investigational reperfusion therapies. The authors postulate that the combination of sonothrombolysis with IV administration of tenecteplase could be a potentially promising therapeutic option deserving further investigation.

There are currently other ongoing studies. ULTRAS study aims to further define the efficacy of ST in acute ischemic stroke, where patients will be randomized to receive either tPA alone or tPA + US. Sonothrombolysis for acute ischemic stroke is also being tested in a pivotal efficacy

multinational trial called CLOTBUSTER<sup>14</sup>, where an operator-independent device, which can be quickly mounted by medical personnel with no prior experience in ultrasound, has a multi-transducer assembly to cover conventional windows used for transcranial Doppler examinations.

Towards to the future, plasmin-loaded echogenic liposomes with ultrasound-mediated release at thrombus site have shown promising results<sup>15</sup> and might be useful in stroke treatment. On the other hand, regarding the influence of ultrasound frequency on ultrasound transmittance through the human skull, and for safer and more efficient sonothrombolysis therapies, accurate estimation of ultrasound transmittance through the human skull is being studied, using modulated waves, which might in the future allow individual adaptation<sup>16</sup>. In conclusion:

- Randomized clinical trials have shown sonothrombolysis to be safe and effective in a faster recanalization of the occluded vessel in acute ischemic stroke.
- A meta-analysis of 6 randomized and 3 nonrandomized clinical studies of sonothrombolysis clarified that any diagnostic ultrasound monitoring can at least double the chance of early complete arterial recanalization at no increase in the risk of symptomatic intracerebral hemorrhage.
- A recent Cochrane review of all the randomized studies published on sonothrombolysis reported significantly more recanalization and better clinical outcome, with no effect on mortality, when sonothrombolysis was added to alteplase in acute ischemic stroke treatment.
- Investigation is ongoing with larger clinical trials to establish the most effective and safe way to apply sonothrombolysis in the routine management of the acute ischemic stroke patient.
- Future possibilities include specific targeting of thrombus with local drug delivery with US-sensitive liposomes.

## References:

<sup>1</sup> Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004 Mar 6;363(9411):768-74.

<sup>2</sup> www.sitsinternational.org

<sup>3</sup> Saqqur M1, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, Akhtar N, Orouk FO, Salam A, Shuaib A, Alexandrov AV; CLOTBUST Investigators. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007 Mar;38(3):948-54. Epub 2007 Feb 8.

<sup>4</sup> Christou I1, Alexandrov AV, Burgin WS, Wojner AW, Felberg RA, Malkoff M, Grotta JC. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial doppler correlates with clinical recovery from ischemic stroke. Stroke. 2000 Aug;31(8):1812-6.

<sup>5</sup> Wardlaw JM1, Koumellis P, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev. 2013 May 31;5:CD000514. doi: 10.1002/14651858.CD000514.pub3.

<sup>6</sup> Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJ, van Walderveen MA, Staals J, Hofmeijer J, van Oostayen JA, Lycklama à Nijeholt GJ, Boiten J, Brouwer PA, Emmer BJ, de Bruijn SF, van Dijk LC, Kappelle LJ, Lo RH, van Dijk EJ, de Vries J, de Kort PL, van Rooij WJ, van den Berg JS, van Hasselt BA, Aerden LA, Dallinga RJ, Visser MC, Bot JC, Vroomen PC, Eshghi O, Schreuder TH, Heijboer RJ, Keizer K, Tielbeek AV, den Hertog HM, Gerrits DG, van den Berg-Vos RM, Karas GB, Steyerberg EW, Flach HZ, Marquering HA, Sprengers ME, Jenniskens SF, Beenen LF, van den Berg R, Koudstaal PJ, van Zwam WH, Roos YB, van der Lugt A, van Oostenbrugge RJ, Majoie CB, Dippel DW; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015 Jan 1;372(1):11-20. doi: 10.1056/NEJMoa1411587. Epub 2014 Dec 17. Erratum in: N Engl J Med. 2015 Jan 22;372(4):394.

<sup>7</sup> Alexandrov AV, Demchuk AM, Felberg RA, Christou I, Barber PA, Burgin WS, Malkoff M, Wojner AW, Grotta JC. High rate of complete recanalization and dramatic clinical recovery

during tPA infusion when continuously monitored with 2-MHz transcranial doppler monitoring. Stroke. 2000 Mar;31(3):610-4.

<sup>8</sup> Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, Montaner J, Saqqur M, Demchuk AM, Moyé LA, Hill MD, Wojner AW; CLOTBUST Investigators. Ultrasoundenhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med. 2004 Nov 18;351(21):2170-8.

<sup>9</sup> Molina CA, Ribo M, Rubiera M, Montaner J, Santamarina E, Delgado-Mederos R, Arenillas JF, Huertas R, Purroy F, Delgado P, Alvarez-Sabín J. Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke. 2006 Feb;37(2):425-9. Epub 2005 Dec 22.

<sup>10</sup> Eggers J1, Seidel G, Koch B, König IR. Sonothrombolysis in acute ischemic stroke for patients ineligible for rt-PA. Neurology. 2005 Mar 22;64(6):1052-4.

<sup>11</sup> Tsivgoulis G1, Eggers J, Ribo M, Perren F, Saqqur M, Rubiera M, Sergentanis TN, Vadikolias K, Larrue V, Molina CA, Alexandrov AV. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke. 2010 Feb;41(2):280-7. doi: 10.1161/STROKEAHA.109.563304. Epub 2009 Dec 31.

<sup>12</sup> Ricci S, Dinia L, Del SetteM, Anzola P,Mazzoli T, Cenciarelli S, Gandolfo C. Sonothrombolysis for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2012,

Issue 10. Art. No.: CD008348. DOI: 10.1002/14651858.CD008348.pub3 <sup>13</sup> Tsivgoulis G, Alleman J, Katsanos AH, Barreto AD, Kohrmann M, Schellinger PD, Molina CA, Alexandrov AV. Comparative efficacy of different acute reperfusion therapies for acute ischemic stroke: a comprehensive benefit-risk analysis of clinical trials. Brain Behav. 2014 Nov;4(6):789-

97. doi: 10.1002/brb3.279. Epub 2014 Sep 11. <sup>14</sup> Zivanović Z, Alexandrov AV, Jesić A, Slankamenac P. Sonothrombolysis: is the story (t)old or just the beginning. Med Pregl. 2014. Jan-Feb:67(1-2):17-23

just the beginning. Med Pregl. 2014 Jan-Feb;67(1-2):17-23. <sup>15</sup> Kandadai MA1, Meunier JM, Hart K, Holland CK, Shaw GJ. Plasmin-loaded echogenic liposomes for ultrasound-mediated thrombolysis. Transl Stroke Res. 2015 Feb;6(1):78-87. doi: 10.1007/s12975-014-0376-4. Epub 2014 Nov 20.

<sup>16</sup> Saito O, Wang Z, Mitsumura H, Ogawa T, Iguchi Y, Yokoyama M. Substantial fluctuation of acoustic intensity transmittance through a bone-phantom plate and its equalization by modulation of ultrasound frequency. Ultrasonics. 2015 May;59:94-101. doi: 10.1016/j.ultras.2015.01.017. Epub 2015 Feb 7.